| (Values in U.S. Thousands) | Mar, 2024 | Mar, 2023 | Mar, 2022 | Mar, 2021 | Mar, 2020 |
| Sales | 110 | 370 | 1,500 | 0 | 2,200 |
| Sales Growth | -70.27% | -75.33% | unch | -100.00% | -28.80% |
| Net Income | -14,670 | -17,260 | -11,450 | -16,830 | -18,710 |
| Net Income Growth | +15.01% | -50.74% | +31.97% | +10.05% | +29.77% |
Organovo Holdings (ONVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Organovo Holdings, Inc. is a three-dimensional biology company focused on delivering breakthrough bioprinting technology and creating tissue on demand for research and medical applications. Its NovoGen 3D printing technology is a platform that works across various tissue and cell types. Organovo Holdings, Inc. is based in San Diego, California.